Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers.

Ruiz-Garcia A, Masters JC, Mendes da Costa L, LaBadie RR, Liang Y, Ni G, Ellery CA, Boutros T, Goldberg Z, Bello CL.

J Clin Pharmacol. 2016 Feb;56(2):223-30. doi: 10.1002/jcph.588. Epub 2015 Oct 9.

PMID:
26179237
2.

A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers.

Ruiz-Garcia A, Giri N, LaBadie RR, Ni G, Boutros T, Richie N, Kocinsky HS, Checchio TM, Bello CL.

J Clin Pharmacol. 2014 May;54(5):555-62. doi: 10.1002/jcph.243. Epub 2013 Dec 17.

PMID:
24293056
3.

A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers.

Bello CL, Smith E, Ruiz-Garcia A, Ni G, Alvey C, Loi CM.

Cancer Chemother Pharmacol. 2013 Aug;72(2):379-85. doi: 10.1007/s00280-013-2207-9. Epub 2013 Jun 13.

PMID:
23760812
4.

The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers.

Bello CL, LaBadie RR, Ni G, Boutros T, McCormick C, Ndongo MN.

Cancer Chemother Pharmacol. 2012 Apr;69(4):991-7. doi: 10.1007/s00280-011-1793-7. Epub 2011 Dec 7.

PMID:
22147075
5.

Exposure-response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice.

Ravaud A, Bello CL.

Anticancer Drugs. 2011 Jun;22(5):377-83. doi: 10.1097/CAD.0b013e3283442039. Review.

PMID:
21394020
6.

Pharmacokinetics of sunitinib malate in subjects with hepatic impairment.

Bello CL, Garrett M, Sherman L, Smeraglia J, Ryan B, Toh M.

Cancer Chemother Pharmacol. 2010 Sep;66(4):699-707. doi: 10.1007/s00280-009-1213-4. Epub 2010 Jan 5.

PMID:
20049443
7.

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ.

Cancer Chemother Pharmacol. 2010 Jul;66(2):357-71. doi: 10.1007/s00280-009-1170-y. Epub 2009 Dec 5. Review.

PMID:
19967539
8.

Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib.

Bello CL, Mulay M, Huang X, Patyna S, Dinolfo M, Levine S, Van Vugt A, Toh M, Baum C, Rosen L.

Clin Cancer Res. 2009 Nov 15;15(22):7045-52. doi: 10.1158/1078-0432.CCR-09-1521. Epub 2009 Nov 10.

9.

Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function.

Khosravan R, Toh M, Garrett M, La Fargue J, Ni G, Marbury TC, Swan SK, Lunde NM, Bello CL.

J Clin Pharmacol. 2010 Apr;50(4):472-81. doi: 10.1177/0091270009347868. Epub 2009 Sep 24.

PMID:
19779038
10.

Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.

Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL, Antonescu CR, George S, Morgan JA, Chen MH, Bello CL, Huang X, Cohen DP, Baum CM, Maki RG.

Clin Cancer Res. 2009 Sep 15;15(18):5902-9. doi: 10.1158/1078-0432.CCR-09-0482. Epub 2009 Sep 8.

11.

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.

Houk BE, Bello CL, Kang D, Amantea M.

Clin Cancer Res. 2009 Apr 1;15(7):2497-506. doi: 10.1158/1078-0432.CCR-08-1893. Epub 2009 Mar 3.

12.

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species.

Haznedar JO, Patyna S, Bello CL, Peng GW, Speed W, Yu X, Zhang Q, Sukbuntherng J, Sweeny DJ, Antonian L, Wu EY.

Cancer Chemother Pharmacol. 2009 Sep;64(4):691-706. doi: 10.1007/s00280-008-0917-1. Epub 2009 Jan 25.

PMID:
19169880
13.

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD.

J Clin Oncol. 2008 Apr 10;26(11):1810-6. doi: 10.1200/JCO.2007.14.5375. Epub 2008 Mar 17.

PMID:
18347007
14.

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.

Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ.

J Transl Med. 2007 Jul 2;5:32.

15.

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.

Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C, Slamon D.

Cancer Chemother Pharmacol. 2008 Mar;61(3):515-24. Epub 2007 May 16.

PMID:
17505827
16.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG.

Lancet. 2006 Oct 14;368(9544):1329-38.

PMID:
17046465
17.

Sunitinib malate for the treatment of solid tumours: a review of current clinical data.

Motzer RJ, Hoosen S, Bello CL, Christensen JG.

Expert Opin Investig Drugs. 2006 May;15(5):553-61. Review.

PMID:
16634693
18.

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects.

Bello CL, Sherman L, Zhou J, Verkh L, Smeraglia J, Mount J, Klamerus KJ.

Anticancer Drugs. 2006 Mar;17(3):353-8.

PMID:
16520665
19.

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI.

J Clin Oncol. 2006 Jan 1;24(1):16-24. Epub 2005 Dec 5.

PMID:
16330672
20.

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

Fiedler W, Serve H, Döhner H, Schwittay M, Ottmann OG, O'Farrell AM, Bello CL, Allred R, Manning WC, Cherrington JM, Louie SG, Hong W, Brega NM, Massimini G, Scigalla P, Berdel WE, Hossfeld DK.

Blood. 2005 Feb 1;105(3):986-93. Epub 2004 Sep 30.

21.

[Nymphal feeding of Leptophlebiidae (Insecta: Ephemeroptera) in the Caño Paso del Diablo, Venezuela].

Bello CL, Cabrera MI.

Rev Biol Trop. 2001 Sep-Dec;49(3-4):999-1003. Spanish.

PMID:
12189832
22.

Functional characteristics and steroid hormone-mediated regulation of an organic cation transporter in Madin-Darby canine kidney cells.

Shu Y, Bello CL, Mangravite LM, Feng B, Giacomini KM.

J Pharmacol Exp Ther. 2001 Oct;299(1):392-8.

Supplemental Content

Loading ...
Support Center